Boehringer / Oncology Partnerships / Eli Lilly and Company / PXS4728A / Eureka Therapeutics Inc. / Zealand Pharma / Hydra Biosciences / Connexios Life Sciences / Pharmaxis / Managing Directors / /
Country
Germany / United States / /
Event
FDA Phase / Business Partnership / M&A / /
Facility
University of Heidelberg / Vanderbilt University / University of Michigan / /
IndustryTerm
chemical probe / treatment of renal diseases / treatment of patients with chronic obstructive pulmonary disease / healthcare / treatment of cancer / treatment for renal diseases / /
University of Heidelberg / Structural Genomics Consortium / European Medicines Agency / US Food and Drug Administration / Vanderbilt University / Innovation Centre / the University of Michigan / /
Person
Johannes Zanzinger / Adrian Carter / Boehringer Ingelheim / Michael Mark / Clive Wood / Andreas Barner / Stephen Fesik / Cheng Liu / Jovan Vitanovski / /
Position
collaboration model at the interface between academia and industry / Vice President / Head / Corporate Head of Research / leader in oncology research and development / Professor / Corporate Vice President / Global Research Networking Boehringer / Vice President / Global Research Networking Boehringer Ingelheim / Corporate SVP and Metabolism Head / President and Chief Executive Officer / Head Global Licensing Cardiometabolic Diseases Obesity Micro / Chairman of the Board / member / /
Product
Pradaxa® / /
ProvinceOrState
Minnesota / Michigan / /
Technology
antibodies / drug discovery / Structural Genomics / /
shutterstock_116875702_yellow.eps